LAUSR

The current COVID‐19 vaccination program requires frequent booster vaccination to maintain sufficient neutralization levels against immune evasive SARS‐CoV‐2 variants. However, prior studies found more potent and durable immune response in convalescing individuals, raising the possibility of less frequent booster vaccination for them. Here, we conducted a longitudinal immunological study based on two prospective cohorts of booster vaccinated convalescing COVID‐19 patients or healthcare workers (HCW) without COVID‐19 history in Xiangyang, China. Comparing to 1‐month post‐boosting, pseudovirus neutralization titers (pVNT50) of ancestral Wuhan‐Hu‐1 and circulating omicron sub‐variants BA.5, BF.7, BA.4.6, BA.2.75, and BA.2.75.2 spikes were stable or even increased in convalescing samples at 6‐month post‐boosting, when HCW samples showed substantial drop of neutralization titers across the spectrum. Variant‐to‐Wuhan‐Hu‐1 pVNT50 ratios showed no significant variation during the 17 months from pre‐vaccination to 6‐month post‐boosting in convalescing individuals, indicating that the high durability of hybrid immunity was likely sustained by continuously improving neutralization potency that compensated immune decay. Our data provide mechanistic insight into prior epidemiological findings that vaccine‐elicited humoral immune response was more durable in convalescing individuals than those without SARS‐CoV‐2 infection, and suggest further research into potential extension of boosting intervals for convalescing individuals.